Immutep Past Earnings Performance

Past criteria checks 0/6

Immutep's earnings have been declining at an average annual rate of -20.8%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 19.5% per year.

Key information

-20.8%

Earnings growth rate

5.7%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate-19.5%
Return on equity-35.0%
Net Margin-1,030.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19
Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How Immutep makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:IMM Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 234-4190
30 Sep 234-4090
30 Jun 234-4090
31 Mar 234-3880
31 Dec 224-3770
30 Sep 225-3470
30 Jun 225-3270
31 Mar 224-2970
31 Dec 214-2670
30 Sep 214-2870
30 Jun 214-3060
31 Mar 215-2960
31 Dec 206-2760
30 Sep 2010-2060
30 Jun 2014-1360
31 Mar 2013-1560
31 Dec 1913-1660
30 Sep 199-1760
30 Jun 196-1860
31 Mar 195-1860
31 Dec 185-1770
30 Sep 186-1570
30 Jun 187-1370
31 Mar 186-1270
31 Dec 177-1060
30 Sep 175-950
30 Jun 174-940
31 Mar 173-1050
31 Dec 162-1050
30 Sep 162-36300
30 Jun 162-62540
31 Mar 162-71540
31 Dec 151-82540
30 Sep 151-57300
30 Jun 151-3260
31 Mar 151-2350
31 Dec 141-1450
30 Sep 142-1450
30 Jun 142-1340
31 Mar 142-1340
31 Dec 132-1350
30 Sep 132-1450

Quality Earnings: IMM is currently unprofitable.

Growing Profit Margin: IMM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IMM is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.

Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.7%).


Return on Equity

High ROE: IMM has a negative Return on Equity (-35.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.